Transthyretin Amyloidosis (ATTR)
Jan 05, 2024
Wainua – The Only Approved Medicine for hATTR-PN Treatment
Ionis Pharmaceuticals and AstraZeneca concluded the year 2023 on a positive note as they received the eagerly awaited approval from the FDA for their transthyretin amyloidosis (ATTR) medication, Wainua. In particular, the agency approved the use of the ligand-conjugated antisense oligonucleotide (LICA) medication f...
Read More...
Jan 24, 2019
BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M
BridgeBio bags USD 299 Million for genetic diseases BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical development. Several therapeutic areas are being taken under the consideration of the pharma. Also, th...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
